GlassScriptPhysician profile
Mark J Allen
NPI 1457465163
$5,794.03
in general payments reported to CMS, 2019-2025
35 companies · $357 in 2025
The $357 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $270 · 2021: $973 · 2022: $668 · 2023: $1,591 · 2024: $1,485 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,368 · Education: $65.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,367.68 |
| Education | $65.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,845.57 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Merck Sharp & Dohme LLC | $500.81 | 2019-2024 | Dificid |
| Janssen Biotech, INC. | $477.87 | 2019-2025 | Tremfya |
| Celgene Corporation | $366.79 | 2021-2024 | Zeposia |
| Daiichi Sankyo INC. | $321.69 | 2019-2025 | Injectafer |
| Qol Medical, LLC | $275.36 | 2020-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $236.38 | 2019-2024 | Entyvio |
| Fresenius Kabi USA, LLC | $219.54 | 2023-2024 | Idacio |
| Pfizer INC. | $207.46 | 2019-2023 | |
| Organon LLC | $206.79 | 2022-2024 | Renflexis, Hadlima |
| Ardelyx, INC. | $197.63 | 2022-2025 | Ibsrela |
| Celltrion USA INC. | $182.45 | 2024-2025 | Vegzelma, Zymfentra |
| E.R. Squibb & Sons, L.L.C. | $120.20 | 2021-2023 | Zeposia |
| Mauna Kea Technologies, INC. | $93.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.65 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $48.53 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $46.21 | 2019-2020 | |
| Amgen INC. | $42.12 | 2021-2023 | Amjevita, Avsola |
| Medtronic, INC. | $35.56 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $31.68 | 2021 | |
| La Jolla Pharmaceutical Company | $31.01 | 2021 | |
| Genzyme Corporation | $29.69 | 2024 | |
| Nestle Healthcare Nutrition INC. | $25.92 | 2023 | |
| Biogen, INC. | $23.65 | 2021 | |
| Echosens North America, INC. | $21.92 | 2022 | |
| Lilly USA, LLC | $21.43 | 2024 | Omvoh |
| Aimmune Therapeutics, INC. | $20.09 | 2024 | |
| Ucb, INC. | $18.81 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $16.82 | 2023-2024 | Biopsy Forceps, Inflation Device |
| Braintree Laboratories, INC. | $15.91 | 2021 | |
| Baudax Bio INC. | $14.80 | 2020 | |
| Phathom Pharmaceuticals, INC. | $13.51 | 2024 | Voquezna |
| Allergan, INC. | $12.21 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.69 | 2019 | |
| Endogastric Solutions, INC | $11.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.